Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 48 pages report, published by Global Markets Direct

Keywords : Peripheral Neuropathy (Sensory Neuropathy) Therapeutic Products under Development, Key Players in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics, Peripheral Neuropathy (Sensory Neuropathy) Pipeline Overview, Peripheral Neuropathy (Sensory Neuropathy) Pipeline, Peripheral Neuropathy (Sensory Neuropathy) Pipeline Assessment

Report ThumbnailSeptember-2013
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Peripheral Neuropathy (Sensory Neuropathy).
- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2013 7
  • Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Discovery and Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 17
  • Assessment by Route of Administration, H2 2013 18
  • Assessment by Stage and Route of Administration, H2 2013 19
  • Assessment by Molecule Type, H2 2013 20
  • Assessment by Stage and Molecule Type, H2 2013 21
  • List of Tables
  • Number of Products Under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2013 7
  • Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Products under Investigation by Universities/Institutes, H2 2013 14
  • Neuren Pharmaceuticals Limited, H2 2013 15
  • Paladin Labs Inc., H2 2013 16
  • Assessment by Monotherapy Products, H2 2013 17
  • Assessment by Stage and Route of Administration, H2 2013 19
  • Assessment by Stage and Molecule Type, H2 2013 21
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Drug Profile Updates 37
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Discontinued Products 39
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Dormant Products 40
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Peripheral Neuropathy (Sensory Neuropathy) Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) 7
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Development by Companies 9
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Investigation by Universities/Institutes 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Discovery and Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Products under Development by Companies 13
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Products under Investigation by Universities/Institutes 14
  • Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development 15
  • Neuren Pharmaceuticals Limited 15
  • Paladin Labs Inc. 16
  • Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment 17
  • Assessment by Monotherapy Products 17
  • Assessment by Route of Administration 18
  • Assessment by Molecule Type 20
  • Drug Profiles 22
  • AL-309 - Drug Profile 22
  • Product Description 22
  • Mechanism of Action 22
  • R&D Progress 22
  • NNZ-2591 - Drug Profile 23
  • Product Description 23
  • Mechanism of Action 23
  • R&D Progress 23
  • NRP-2945 - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • flupirtine maleate - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • MAC-i Class II - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • Nanoparticle Complement Inhibitors - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Compounds For Peripheral Neuropathy - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Neural Regeneration Peptides For Peripheral Neuropathy - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • Dorsal Root Ganglion Targeting Peptides - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Glucagon Like Peptide-1 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Glucagon Like Peptide-1 Analogues - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Drug Profile Updates 37
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Discontinued Products 39
  • Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Dormant Products 40
  • Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones 41
  • Featured News & Press Releases 41
  • Jul 12, 2013: Neuren Receives Notice of Allowance for Two New Patents 41
  • Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent 41
  • Dec 10, 2012: Spinifex Pharma Starts Phase II Proof-of-concept Trial Of EMA401 In Chemotherapy-induced Peripheral Neuropathy 42
  • Feb 07, 2011: EpiCept Reports Positive Results From EpiCept NP-1 Trial In Patients With Chemotherapy-Induced Peripheral Neuropathy 43
  • Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer 43
  • Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 44
  • Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 44
  • May 28, 2010: Relevare Pharmaceuticals Presents Latest Clinical Trial Data On CNSB015 At Third International Congress On Neuropathic Pain In Athens, Greece 45
  • Apr 06, 2010: Pfizer told to Pay $142.1 million for Neurontin marketing violations. 45
  • Feb 24, 2010: Allon Reports Preclinical Efficacy Data Of AL-309 For Treatment Of Peripheral Neuropathy 46
  • Appendix 47
  • Methodology 47
  • Coverage 47
  • Secondary Research 47
  • Primary Research 47
  • Expert Panel Validation 47
  • Contact Us 48
  • Disclaimer 48

Please select a license type

Share

Related Products

Global Markets DirectPeripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2013Product ThumbnailPeripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2013, Industry ReportProduct #: 113330
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved